| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Bret R Rutherford | |
| Steven P Roose | |||
| P2860 | cites work | Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration | Q21092366 |
| Antidepressant drug effects and depression severity: a patient-level meta-analysis | Q24598580 | ||
| Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 | ||
| Interrater reliability in clinical trials of depressive disorders | Q33184225 | ||
| Personality change during depression treatment: a placebo-controlled trial | Q33562048 | ||
| Placebo response in studies of major depression: variable, substantial, and growing | Q34122652 | ||
| Are placebo controls necessary to test new antidepressants and anxiolytics? | Q52944433 | ||
| Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? | Q53016157 | ||
| Is it easier to find what you are looking for if you think you know what it looks like? | Q53020544 | ||
| The impact of restrictive entry criterion during the placebo lead-in period. | Q54375984 | ||
| Long-term outcome of episodes of major depression. Clinical and public health significance | Q60447183 | ||
| The physician's actions and the outcome of illness in family practice | Q69550834 | ||
| Delusional depression. A distinct clinical entity? | Q70718323 | ||
| Are drug and placebo effects in depression additive? | Q73693593 | ||
| Cost-effectiveness of treatments for major depression in primary care practice | Q74794147 | ||
| Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? | Q84080390 | ||
| The functional neuroanatomy of the placebo effect | Q34126324 | ||
| The placebo effect: dissolving the expectancy versus conditioning debate. | Q34300478 | ||
| Regression to the mean: what it is and how to deal with it. | Q34343839 | ||
| The double-blind variable placebo lead-in period: results from two antidepressant clinical trials | Q34474851 | ||
| Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective | Q34493774 | ||
| Negative effects from psychological treatments: a perspective | Q34615568 | ||
| Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses | Q34634132 | ||
| The persistence of the placebo response in antidepressant clinical trials | Q34717970 | ||
| Meta-analysis of the placebo response in antidepressant trials | Q34952811 | ||
| Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact | Q35127347 | ||
| Context effects. Powerful therapies or methodological bias? | Q35146758 | ||
| Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review | Q36432995 | ||
| Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram | Q36695387 | ||
| Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis | Q36777132 | ||
| Mechanisms of placebo and placebo-related effects across diseases and treatments | Q36897426 | ||
| Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression | Q36999317 | ||
| Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials | Q37202188 | ||
| Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. | Q37281749 | ||
| Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder | Q37338715 | ||
| Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. | Q37685313 | ||
| Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial | Q38400118 | ||
| Zung, Beck, and Hamilton Rating Scales as measures of treatment outcome: a meta-analytic comparison | Q38477874 | ||
| Placebo in emotional processing--induced expectations of anxiety relief activate a generalized modulatory network | Q39365805 | ||
| On placebos, placebo responses and placebo responders. A review of psychological, psychopharmacological and psychophysiological factors. II. Psychopharmacological and psychophysiological factors | Q40351212 | ||
| Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. | Q40471950 | ||
| Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling | Q41874724 | ||
| Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial | Q43553517 | ||
| A meta-analysis of antidepressant outcome under "blinder" conditions | Q43713318 | ||
| Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. | Q45058743 | ||
| Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial | Q45130101 | ||
| Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model | Q45349953 | ||
| National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the national comorbidity survey replication. | Q46655034 | ||
| Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs | Q46911904 | ||
| Antidepressant clinical trials and subject recruitment: just who are symptomatic volunteers? | Q48777192 | ||
| ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. | Q51700487 | ||
| Frequency of follow-up care for adult and pediatric patients during initiation of antidepressant therapy. | Q51914056 | ||
| Duration of untreated symptoms in common mental disorders: association with outcomes: International study. | Q51915306 | ||
| Rater bias in a blinded randomized placebo-controlled psychiatry trial. | Q51923341 | ||
| Treatment expectancies, patient alliance, and outcome: further analyses from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. | Q51953847 | ||
| Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? | Q52024630 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| P304 | page(s) | 723-733 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | A model of placebo response in antidepressant clinical trials | |
| P478 | volume | 170 |
| Q49342341 | A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials |
| Q37054983 | A Meta-Analysis of Executive Dysfunction and Antidepressant Treatment Response in Late-Life Depression |
| Q48125500 | A Question of Control? Examining the Role of Control Conditions in Experimental Psychopathology using the Example of Cognitive Bias Modification Research |
| Q90099416 | A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints |
| Q37651165 | A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder |
| Q33632732 | A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder |
| Q37077152 | A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder |
| Q34093154 | An open treatment trial of duloxetine in elderly patients with dysthymic disorder |
| Q46624891 | Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder |
| Q47553358 | Antidepressants for depression in adults with HIV infection |
| Q34495779 | Antidepressants versus placebo in major depression: an overview |
| Q48064604 | Are antidepressants and psychotherapy equally effective in treating depression? A critical commentary |
| Q30398592 | Beyond expectation: a case for nonpersonal contextual factors in a more comprehensive approach to the placebo effect and the contribution of environmental psychology. |
| Q93172176 | Biomedical Explanations of Psychopathology and Their Implications for Attitudes and Beliefs About Mental Disorders |
| Q47707859 | Castration Depression: Affect, Signal Affect, and/or Depressive Illness? |
| Q38680293 | Challenges Establishing the Efficacy of Exercise as an Antidepressant Treatment: A Systematic Review and Meta-Analysis of Control Group Responses in Exercise Randomised Controlled Trials |
| Q90304129 | Challenges of differential placebo effects in contemporary medicine: The example of brain stimulation |
| Q36553909 | Changes in causal attributions and relationship representations: Are they specific or common mechanisms in the treatment of depression? |
| Q35672140 | Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial |
| Q35559020 | Clinical presentation and pharmacotherapy response in social anxiety disorder: The effect of etiological beliefs |
| Q52687120 | Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. |
| Q47693093 | Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder |
| Q42650671 | Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial |
| Q37695542 | Does the model of additive effect in placebo research still hold true? A narrative review |
| Q53444896 | Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016. |
| Q50005086 | Effects of Rate on Analgesia in Kilohertz Frequency Spinal Cord Stimulation: Results of the PROCO Randomized Controlled Trial |
| Q47772123 | Efficacy of antidepressants: bias in randomized clinical trials and related issues |
| Q47725533 | Expectancy Effects in Self-Help Depression Treatment: First Evidence that the Rationale Given for an Online Study Impacts the Outcome |
| Q44174682 | Expectancy after the first treatment and response to acupuncture for menopausal hot flashes |
| Q41411906 | Factors contributing to the increasing placebo response in antidepressant trials. |
| Q54974160 | Factors impacting the efficacy of venlafaxine extended release 75-225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan. |
| Q36601436 | From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant Findings |
| Q36370168 | Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013. |
| Q90049422 | How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis |
| Q37041164 | INFLUENCE OF STUDY DESIGN ON TREATMENT RESPONSE IN ANXIETY DISORDER CLINICAL TRIALS |
| Q54940914 | Individual Differences in Expectancies for Change in Depression: Associations with Goal Pursuit and Daily Experiences. |
| Q91938094 | Is High Placebo Response Really a Problem in Depression Trials? A Critical Re-analysis of Depression Studies |
| Q38194534 | Journal Watch review of Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial |
| Q37503551 | Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout |
| Q38255663 | Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder |
| Q38243819 | Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning |
| Q90406577 | Meta-Analysis of Placebo Response in Adult Antidepressant Trials |
| Q47248824 | Methods for assessing and controlling placebo effects. |
| Q38766369 | Modifiers of Response to Treatment With Fesoterodine for Urgency-Predominant Urinary Incontinence in a Randomized Controlled Trial |
| Q92140070 | Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study |
| Q61806952 | Not Just Nonspecific Factors: The Roles of Alliance and Expectancy in Treatment, and Their Neurobiological Underpinnings |
| Q93012362 | Optimizing patient expectancy in the pharmacologic treatment of major depressive disorder |
| Q39409071 | Patient Expectancy as a Mediator of Placebo Effects in Antidepressant Clinical Trials |
| Q39878590 | Placebo Response in Pediatric Anxiety Disorders: Implications for Clinical Trial Design and Interpretation |
| Q33586880 | Placebo effect in clinical trial design for irritable bowel syndrome |
| Q33803327 | Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism. |
| Q35097020 | Placebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictors |
| Q34443837 | Placebo response in antipsychotic clinical trials: a meta-analysis |
| Q38802744 | Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. |
| Q35175987 | Positive Imagery-Based Cognitive Bias Modification as a Web-Based Treatment Tool for Depressed Adults: A Randomized Controlled Trial |
| Q37347743 | Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis |
| Q36984739 | Psychiatrists' Attitudes Toward Non-Pharmacologic Factors Within the Context of Antidepressant Pharmacotherapy |
| Q64244337 | Psychobiological factors of resilience and depression in late life |
| Q47701615 | Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial. |
| Q34108860 | Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study |
| Q57175049 | Resilience predicts remission in antidepressant treatment of geriatric depression |
| Q26776255 | Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions |
| Q38728148 | Safety of Repeated-Dose Intratympanic Injections with AM-101 in Acute Inner Ear Tinnitus. |
| Q38759815 | Side effects can enhance treatment response through expectancy effects: an experimental analgesic randomized controlled trial |
| Q47149850 | Specific expectancies are associated with symptomatic outcomes and side effect burden in a trial of chamomile extract for generalized anxiety disorder |
| Q89483192 | Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization |
| Q91518890 | The antidepressant standoff: why it continues and how to resolve it |
| Q58802217 | The conundrum of depression clinical trials: one size does not fit all |
| Q34531579 | The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study |
| Q38181363 | The integrative management of treatment-resistant depression: a comprehensive review and perspectives |
| Q34458264 | The role of patient expectancy in placebo and nocebo effects in antidepressant trials |
| Q35562674 | Therapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels? |
| Q93135895 | Trim the fat: the role of omega-3 fatty acids in psychopharmacology |
| Q90456469 | WITHDRAWN: Size Does Matter, But It Isn't Everything: The Challenge of Modest Treatment Effects in Chronic Pain Clinical Trials |
| Q91847465 | When All Else Fails, Listen to the Patient: A Viewpoint on the Use of Ecological Momentary Assessment in Clinical Trials |
Search more.